Neuronetics, Inc. (STIM)

Market Cap	37.82M
Revenue (ttm)	67.85M
Net Income (ttm)	-31.32M
Shares Out	28.87M
EPS (ttm)	-1.13
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	55,864
Open	1.31
Previous Close	1.33
Day's Range	1.25 - 1.34
52-Week Range	1.25 - 6.95
Beta	1.83
Analysts	Strong Buy
Price Target	9.50 (+625.19%)
Earnings Date	Nov 7, 2023

About STIM

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jun 28, 2018
• Employees: 209
• Stock Exchange: NASDAQ
• Ticker Symbol: STIM

Financial Performance

In 2022, Neuronetics's revenue was $65.21 million, an increase of 17.89% compared to the previous year's $55.31 million. Losses were -$37.16 million, 19.1% more than in 2021.

Analyst Forecast

According to 2 analysts, the average rating for STIM stock is "Strong Buy." The 12-month stock price forecast is $9.5, which is an increase of 625.19% from the latest price.

Price Target

$9.5

(625.19% upside)

Analyst Consensus: Strong Buy